Barclays lowered the firm’s price target on Tandem Diabetes (TNDM) to $51 from $53 and keeps an Overweight rating on the shares. The firm views the stock as “significantly oversold” post earnings and believes the pullback provides an attractive buying opportunity.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Positive Outlook for Tandem Diabetes Care: Buy Rating Reaffirmed Amid Growth Catalysts and Strategic Opportunities
- Tandem Diabetes Care’s Earnings Call Highlights Growth and Challenges
- Tandem Diabetes Care Gains FDA Clearance for SteadiSet
- Tandem Diabetes price target lowered to $20 from $27 at TD Cowen
- Tandem Diabetes price target lowered to $24 from $59 at Canaccord